CHAI and LATAIE: New genetic diseases of CTLA-4 checkpoint insufficiency

Blood

Volumn 128, Issue 8, 2016, Pages 1037-1042

  Lo, Bernice ^a,b,c   Fritz, Jill M ^b,c   Su, Helen C ^c,d   Uzel, Gulbu ^e   Jordan, Michael B ^f,g   Lenardo, Michael J ^b,c  

^a SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^b Laboratory of Immunology   (United States)

^c Clinical Genomics Program   (United States)

^d Laboratory of Host Defenses   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f Bone Marrow Transplantation and Immune Deficiency   (United States)

^g UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY;

ARTICLE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CLINICAL FEATURE; CTLA 4 HAPLOINSUFFICIENCY WITH AUTOIMMUNE INFILTRATION; GENE MUTATION; GENETIC DISORDER; HUMAN; IMMUNE DYSREGULATION; LRBA DEFICIENCY WITH AUTOANTIBODIES REGULATORY T CELL DEFECTS AUTOIMMUNE INFILTRATION AND ENTEROPATHY; PATHOGENESIS; PHARMACEUTICAL CARE; PRIORITY JOURNAL; TREATMENT INDICATION; CELL CYCLE CHECKPOINT; GENETICS; IMMUNE SYSTEM DISEASES; IMMUNOTHERAPY; MUTATION; PHENOTYPE;

CELL CYCLE CHECKPOINTS; CTLA-4 ANTIGEN; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOTHERAPY; MUTATION; PHENOTYPE;

EID: 84984801447     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-04-712612     Document Type: Article

References (48)

1. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230): 56-61.
2. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995; 270(5238):985-988.
3. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3(5):541-547.
4. Kuehn HS, Ouyang W, Lo B, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 2014;345(6204):1623-1627.
5. Schubert D, Bode C, Kenefeck R, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014; 20(12):1410-1416.
6. Lopez-Herrera G, Tampella G, Pan-Hammarström Q, et al. Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity. Am J Hum Genet. 2012;90(6):986-1001.
7. Alangari A, Alsultan A, Adly N, et al. LPSresponsive beige-like anchor (LRBA) gene mutation in a family with inflammatory bowel disease and combined immunodeficiency. J Allergy Clin Immunol. 2012;130(2):481-488.
8. Burns SO, Zenner HL, Plagnol V, et al. LRBA gene deletion in a patient presenting with autoimmunity without hypogammaglobulinemia. J Allergy Clin Immunol. 2012;130(6):1428-1432.
9. Charbonnier LM, Janssen E, Chou J, et al. Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA. J Allergy Clin Immunol. 2015; 135(1):217-227.
10. Seidel MG, Hirschmugl T, Gamez-Diaz L, et al. Long-term remission after allogeneic hematopoietic stem cell transplantation in LPS-responsive beige-like anchor (LRBA) deficiency. J Allergy Clin Immunol. 2015;135(5):1384-1390.
11. Revel-Vilk S, Fischer U, Keller B, et al. Autoimmune lymphoproliferative syndrome-like disease in patients with LRBA mutation. Clin Immunol. 2015;159(1):84-92.
12. Lo B, Zhang K, Lu W, et al. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science. 2015;349(6246):436-440.
13. Sari S, Dogu F, Hwa V, et al. A successful HSCT in a girl with novel LRBA mutation with refractory celiac disease. J Clin Immunol. 2016;36(1):8-11.
14. Schreiner F, Plamper M, Dueker G, et al. Infancy-onset T1DM, short stature, and severe immunodysregulation in two siblings with a homozygous LRBA mutation. J Clin Endocrinol Metab. 2016;101(3):898-904.
15. Price S, Shaw PA, Seitz A, et al. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood. 2014;123(13):1989-1999.
16. Hayakawa S, Okada S, Tsumura M, et al. A patient with CTLA-4 haploinsufficiency presenting gastric cancer. J Clin Immunol. 2016;36(1):28-32.
17. Alkhairy OK, Abolhassani H, Rezaei N, et al. Spectrum of phenotypes associated with mutations in LRBA. J Clin Immunol. 2016;36(1): 33-45.
18. Gámez-Díaz L, August D, Stepensky P, et al. The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency. J Allergy Clin Immunol. 2016;137(1):223-230.
19. Wing K, Yamaguchi T, Sakaguchi S. Cellautonomous and non-autonomous roles of CTLA-4 in immune regulation. Trends Immunol. 2011;32(9):428-433.
20. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011;11(12): 852-863.
21. Collins AV, Brodie DW, Gilbert RJ, et al. The interaction properties of costimulatory molecules revisited. Immunity. 2002;17(2):201-210.
22. Qureshi OS, Zheng Y, Nakamura K, et al. Transendocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011;332(6029):600-603.
23. Gross JA, Callas E, Allison JP. Identification and distribution of the costimulatory receptor CD28 in the mouse. J Immunol. 1992;149(2):380-388.
24. Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, Mittler RS. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity. 1996;4(6):535-543.
25. Read S, Malmström V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(1)CD4(1) regulatory cells that control intestinal inflammation. J Exp Med. 2000;192(2):295-302.
26. Mead KI, Zheng Y, Manzotti CN, et al. Exocytosis of CTLA-4 is dependent on phospholipase D and ADP ribosylation factor-1 and stimulated during activation of regulatory T cells. J Immunol. 2005; 174(8):4803-4811.
27. Qureshi OS, Kaur S, Hou TZ, et al. Constitutive clathrin-mediated endocytosis of CTLA-4 persists during T cell activation. J Biol Chem. 2012; 287(12):9429-9440.
28. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp31 regulatory T cell function. Science. 2008;322(5899):271-275.
29. Wang JW, Howson J, Haller E, Kerr WG. Identification of a novel lipopolysaccharideinducible gene with key features of both A kinase anchor proteins and chs1/beige proteins. J Immunol. 2001;166(7):4586-4595.
30. de Souza N, Vallier LG, Fares H, Greenwald I. SEL-2, the C. elegans neurobeachin/LRBA homolog, is a negative regulator of lin-12/Notch activity and affects endosomal traffic in polarized epithelial cells. Development. 2007;134(4): 691-702.
31. Wang CJ, Heuts F, Ovcinnikovs V, et al. CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci USA. 2015;112(2):524-529.
32. Wing JB, Ise W, Kurosaki T, Sakaguchi S. Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4. Immunity. 2014;41(6):1013-1025.
33. Sage PT, Paterson AM, Lovitch SB, Sharpe AH. The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. Immunity. 2014;41(6):1026-1039.
34. Moir S, Ho J, Malaspina A, et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIVinfected viremic individuals. J Exp Med. 2008; 205(8):1797-1805.
35. Isnardi I, Ng YS, Menard L, et al. Complement receptor 2/CD21- human naive B cells containmostly autoreactive unresponsive clones. Blood. 2010;115(24):5026-5036.
36. Lee S, Moon JS, Lee CR, et al. Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4. J Allergy Clin Immunol. 2016;137(1):327-330.
37. Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG. Rapamycin promotes expansion of functional CD41CD251FOXP31 regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol. 2006;177(12):8338-8347.
38. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD41CD251 FoxP31 regulatory T cells. Blood. 2005;105(12): 4743-4748.
39. Hippen KL, Merkel SC, Schirm DK, et al. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med. 2011;3(83): 83ra41.
40. Zeiser R, Leveson-Gower DB, Zambricki EA, et al. Differential impact of mammalian target of rapamycin inhibition on CD41CD251Foxp31 regulatory T cells compared with conventional CD41 T cells. Blood. 2008;111(1):453-462.
41. The HERA Study Group. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study. Am J Med. 1995;98(2):156-168.
42. Clegg DO, Dietz F, Duffy J, et al. Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine. J Rheumatol. 1997;24(10):1896-1902.
43. Costedoat-Chalumeau N, Dunogué B, Morel N, Le Guern V, Guettrot-Imbert G. Hydroxychloroquine: a multifaceted treatment in lupus. Presse Med. 2014;43(6, pt 2):e167-e180.
44. Tesi B, Priftakis P, Lindgren F, et al. Successful hematopoietic stem cell transplantation in a patient with LPS-responsive beige-like anchor (LRBA) gene mutation. J Clin Immunol. 2016;36(5):480-489.
45. Slatter MA, Engelhardt KR, Burroughs LM, et al. Hematopoietic stem cell transplantation for CTLA4 deficiency [published online ahead of print April 18, 2016]. J Allergy Clin Immunol. doi: 10.1016/j.jaci.2016.01.045.
46. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-723.
47. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-2526.
48. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21): 2691-2697.